Skip NavigationSkip to Content
Return Return to Search Results

Griffithsin Inhibits Nipah Virus Entry and Fusion and Can Protect Syrian Golden Hamsters From Lethal Nipah Virus Challenge

  1. Author:
    Lo, Michael K
    Spengler, Jessica R
    Haugh Krumpe,Lauren
    Welch, Stephen R
    Chattopadhyay, Anasuya
    Harmon, Jessica R
    Coleman-McCray, Joann D
    Scholte, Florine E M
    Hotard, Anne L
    Fuqua, Joshua L
    Rose, John K
    Nichol, Stuart T
    Palmer, Kenneth E
    O'Keefe,Barry
    Spiropoulou, Christina F

  2. Author Address

    Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Yale University School of Medicine, New Haven, Connecticut, USA., Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville School of Medicine, Louisville, Kentucky, USA., Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA., Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland, USA.,
    1. Year: 2020
    2. Date: MAY 1
    3. Epub Date: 2020 02 10
  2. Journal: The Journal of infectious diseases
    1. 221
    2. Supp. 4
    3. Pages: S480-S492
  4. Type of Article: Article
  5. ISSN: 0022-1899
  1. Abstract:

    Nipah virus (NiV) is a highly pathogenic zoonotic paramyxovirus that causes fatal encephalitis and respiratory disease in humans. There is currently no approved therapeutic for human use against NiV infection. Griffithsin (GRFT) is high-mannose oligosaccharide binding lectin that has shown in vivo broad-spectrum activity against viruses including severe acute respiratory syndrome coronavirus, human immunodeficiency virus 1, hepatitis C virus, and Japanese encephalitis virus. In this study, we evaluated the in vitro antiviral activities of GRFT and its synthetic trimeric tandemer (3mG) against NiV and other viruses from across 4 virus families. The 3mG had comparatively greater potency than GRFT against NiV due to its enhanced ability to block NiV glycoprotein-induced syncytia formation. Our initial in vivo prophylactic evaluation of an oxidation-resistant GRFT (Q-GRFT) showed significant protection against lethal NiV challenge in Syrian golden hamsters. Our results warrant further development of Q-GRFT and 3mG as potential NiV therapeutics. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1093/infdis/jiz630
  3. PMID: 32037447
  4. View record in Web of Science®
  5. WOS: 000553463400018
  6. PII : 5731546

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel